Cargando…

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma

Detalles Bibliográficos
Autores principales:	Tang, Jing, Li, Yue, Wu, Jiazhu, Shen, Haorui, Yin, Hua, Liang, Jinhua, Wang, Li, Li, Jianyong, Xia, Yi, Xu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2023
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491910/ https://www.ncbi.nlm.nih.gov/pubmed/37692509 http://dx.doi.org/10.1016/j.gendis.2023.04.012

Ejemplares similares

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
por: Xavier, Flávia Dias, et al.
Publicado: (2014)

Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
por: Voropaeva, Elena N., et al.
Publicado: (2019)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022)

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
por: Pasqualucci, Laura, et al.
Publicado: (2006)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
por: Fang, Ying, et al.
Publicado: (2023)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: A retrospective single-center study
por: Wu, Jiazhu, et al.
Publicado: (2021)

The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma
por: Bian, Zhouliang, et al.
Publicado: (2023)

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo
por: Damm, Jesper Kofoed, et al.
Publicado: (2015)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Identification of TP53 mutation-associated prognostic genes and investigation of the immune cell infiltration in patients with hepatocellular carcinoma
por: Yang, Qijun, et al.
Publicado: (2023)

P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS
por: Uppal, Manik, et al.
Publicado: (2023)

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
por: Cai, Yiqing, et al.
Publicado: (2023)

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
por: Cao, Yang, et al.
Publicado: (2016)

A novel TP53 tandem duplication in a child with Li–Fraumeni syndrome
por: Xu, Feng, et al.
Publicado: (2022)

Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma
por: Li, Xinyi, et al.
Publicado: (2023)

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion
por: Sinkoff, Jillian, et al.
Publicado: (2017)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
por: Jin, Xuan, et al.
Publicado: (2012)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

TP53 and XRCC1 polymorphisms and breast cancer prognosis: a case-case study
por: Rodrigues, Marina Silva, et al.
Publicado: (2011)

Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters
por: Filho, Eduardo Henrique Cunha Neves, et al.
Publicado: (2023)

Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
por: Asmar, Fazila, et al.
Publicado: (2014)

A nomogram for predicting the rapid progression of diffuse large B‐cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations
por: Liu, Cong, et al.
Publicado: (2023)

Trans‐regulated Silencing and Reactivation of TP53 Tumor Suppressor Gene in Malignant Transformation and Its Reversion
por: Yang, Lichun, et al.
Publicado: (2000)

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population
por: Levy, Débora, et al.
Publicado: (2011)

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
por: Miao, Yi, et al.
Publicado: (2019)

Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial
por: Xia, Yi, et al.
Publicado: (2023)

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis
por: Dobashi, Akito, et al.
Publicado: (2018)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

The protective effects of lafutidine for bortezomib induced peripheral neuropathy
por: Tsukaguchi, Machiko, et al.
Publicado: (2013)

Multiple primary malignancies in 788 Chinese patients with diffuse large B‐cell lymphoma
por: Zhang, Xuchang, et al.
Publicado: (2023)

Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer
por: Mitamura, Takashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_te755rsjej3q2cikh0ovd0he7i